SEC Form 4 · accession 0001209191-15-027513

ChemoCentryx, Inc. · CCXI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Mar 16, 2015

Accepted (ET)

Mar 18, 2015 · 4:50 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001340652

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 16, 2015	M	22,726	$0.60	A	2,171,393	D
Common Stock^F2,F3	Mar 16, 2015	S	22,726	$8.5421	D	2,148,667	D
Common Stock	Mar 17, 2015	M	8,590	$0.60	A	2,157,257	D
Common Stock^F2,F4	Mar 17, 2015	S	8,590	$8.5788	D	2,148,667	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F5	$0.60	Mar 16, 2015	M	22,726	D	May 5, 2005	May 5, 2015	Common Stock	22,726	102,274	D
Stock Option (right to buy)^F5	$0.60	Mar 17, 2015	M	8,590	D	May 5, 2005	May 5, 2015	Common Stock	8,590	93,684	D

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2Shares sold are associated with stock options which will expire in May 2015.
F3Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $8.37 to $8.7186 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F4Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $8.3695 to $8.70 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F5As of March 16, 2015 and prior to this transaction, the option fully vested.